BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...Germany’s PentixaPharm GmbH raised $25 million and $16.6 million private rounds last year, respectively, while Actinium Pharmaceuticals Inc....
...OSE:NANOV) raised $53 million on the public markets. Karen Tkach Tuzman Point Biopharma Inc. Aktis Oncology Fusion Pharmaceuticals Inc. RayzeBio Inc. Actinium Pharmaceuticals Inc. Nordic...
BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

...on KOSDAQ early this year. BC Staff BeiGene Ltd. eGenesis Inc. Omniome Inc. Bioventus Inc. Dyne Therapeutics Inc. Axcella Health Inc. Prometheus Biosciences Inc. Actinium Pharmaceuticals Inc. NeoImmuneTech...
BioCentury | Jan 16, 2021
Product Development

Jan. 15 Quick Takes: Darzalex gains first FDA approval for form of amyloidosis; plus Thermo Fisher, Lilly, DBV, Dr. Reddy’s, Alexion, Taiho, Astellas-Actinium

...and commercial hub for its European business.Astellas, Actinium in radiotherapy deal Astellas Pharma Inc. (Tokyo:4503) partnered with Actinium Pharmaceuticals Inc....
BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

...Scientific Inc. (NYSE:TMO), where he was VP and general manager, protein and cell analysis. Radiotherapy play Actinium Pharmaceuticals Inc....
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...more funds if multiple targets gain traction simultaneously.Actinium Pharmaceuticals Inc....
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...saying, ‘wow, we need to take this seriously again,’” Sandesh Seth, CEO of radiotherapy play Actinium Pharmaceuticals Inc....
...Tkach Tuzman, Associate Editor Lutathera (Brand), 177-Lu-Dotatate (Informal), 177Lu-DOTA0-Tyr3-Octreotate (Informal), Lutetium Lu 177 Dotatate (Other) Novartis AG Bayer AG Actinium Pharmaceuticals Inc. Orano...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:MBIO) 4/30/19 $31.6 $157.0 $145.0 -8% Gritstone Oncology Inc. (NASDAQ:GRTS) 4/24/19 $74.8 $410.5 $397.9 -3% Actinium Pharmaceuticals Inc....
BioCentury | Dec 28, 2018
Company News

Management tracks: Schwartz steps down as Kadmon chairman

...from November 2015 to June 2017, was most recently EVP, head of product development at Actinium Pharmaceuticals Inc....
BioCentury | Jan 5, 2018
Clinical News

Actinium reports Phase II data for Actimab-A in AML

...anti-CD33 mAb lintuzumab (HuM195). The product has Orphan Drug designation in the U.S. and Europe. Actinium Pharmaceuticals Inc....
...PFS), leukemia-free survival (LFS) and overall survival (OS) Status: Preliminary Phase II data Milestone: NA Alicia Parker Actimab-A Actinium Pharmaceuticals Inc. CD33...
BioCentury | Oct 6, 2017
Finance

High as a Kite

...8/3/17 $402.5 $2,777.5 $3,258.5 17% Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) 7/28/17 $17.3 $181.1 $193.2 7% Actinium Pharmaceuticals Inc....
Items per page:
1 - 10 of 54
BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...Germany’s PentixaPharm GmbH raised $25 million and $16.6 million private rounds last year, respectively, while Actinium Pharmaceuticals Inc....
...OSE:NANOV) raised $53 million on the public markets. Karen Tkach Tuzman Point Biopharma Inc. Aktis Oncology Fusion Pharmaceuticals Inc. RayzeBio Inc. Actinium Pharmaceuticals Inc. Nordic...
BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

...on KOSDAQ early this year. BC Staff BeiGene Ltd. eGenesis Inc. Omniome Inc. Bioventus Inc. Dyne Therapeutics Inc. Axcella Health Inc. Prometheus Biosciences Inc. Actinium Pharmaceuticals Inc. NeoImmuneTech...
BioCentury | Jan 16, 2021
Product Development

Jan. 15 Quick Takes: Darzalex gains first FDA approval for form of amyloidosis; plus Thermo Fisher, Lilly, DBV, Dr. Reddy’s, Alexion, Taiho, Astellas-Actinium

...and commercial hub for its European business.Astellas, Actinium in radiotherapy deal Astellas Pharma Inc. (Tokyo:4503) partnered with Actinium Pharmaceuticals Inc....
BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

...Scientific Inc. (NYSE:TMO), where he was VP and general manager, protein and cell analysis. Radiotherapy play Actinium Pharmaceuticals Inc....
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...more funds if multiple targets gain traction simultaneously.Actinium Pharmaceuticals Inc....
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...saying, ‘wow, we need to take this seriously again,’” Sandesh Seth, CEO of radiotherapy play Actinium Pharmaceuticals Inc....
...Tkach Tuzman, Associate Editor Lutathera (Brand), 177-Lu-Dotatate (Informal), 177Lu-DOTA0-Tyr3-Octreotate (Informal), Lutetium Lu 177 Dotatate (Other) Novartis AG Bayer AG Actinium Pharmaceuticals Inc. Orano...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:MBIO) 4/30/19 $31.6 $157.0 $145.0 -8% Gritstone Oncology Inc. (NASDAQ:GRTS) 4/24/19 $74.8 $410.5 $397.9 -3% Actinium Pharmaceuticals Inc....
BioCentury | Dec 28, 2018
Company News

Management tracks: Schwartz steps down as Kadmon chairman

...from November 2015 to June 2017, was most recently EVP, head of product development at Actinium Pharmaceuticals Inc....
BioCentury | Jan 5, 2018
Clinical News

Actinium reports Phase II data for Actimab-A in AML

...anti-CD33 mAb lintuzumab (HuM195). The product has Orphan Drug designation in the U.S. and Europe. Actinium Pharmaceuticals Inc....
...PFS), leukemia-free survival (LFS) and overall survival (OS) Status: Preliminary Phase II data Milestone: NA Alicia Parker Actimab-A Actinium Pharmaceuticals Inc. CD33...
BioCentury | Oct 6, 2017
Finance

High as a Kite

...8/3/17 $402.5 $2,777.5 $3,258.5 17% Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) 7/28/17 $17.3 $181.1 $193.2 7% Actinium Pharmaceuticals Inc....
Items per page:
1 - 10 of 54